[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-426724-105":59,"doc-detail-426724-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","perceptions-of-value-and-adoption-of-adrd-modifying-drugs-among-physicians-around-the-us","Perceptions of Value and Adoption of ADRD Modifying Drugs Among Physicians Around the U.S.","","Study of physician perspectives on the perceived value and real-world adoption of two newly FDA-approved anti-amyloid monoclonal antibodies for Alzheimer’s Disease—lecanemab and donanemab. The work addresses how clinicians conduct risk-benefit evaluations when selecting candidates, and what practice-level, insurance, and health-system barriers affect implementation. Qualitative interviews with 10 physicians explored adoption drivers and obstacles, communication approaches to patients and families, and ethical and emotional challenges while balancing hope with limited evidence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/perceptions-of-value-and-adoption-of-adrd-modifying-drugs-among-physicians-around-the-us/426724/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/perceptions-of-value-and-adoption-of-adrd-modifying-drugs-among-physicians-around-the-us/426724.png","ImageObject",300,407,{"name":92,"@type":93},"SANS","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-15","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study aiming to understand about anti-amyloid medications?","Question",{"text":112,"@type":113},"It examined clinicians’ perceptions of the value of lecanemab and donanemab and their real-world experiences adopting these therapies in practice.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers gather evidence?",{"text":117,"@type":113},"They used purposive and snowball sampling to interview 10 physicians, including geriatricians, neurologists, and psychiatrists.",{"name":119,"@type":110,"acceptedAnswer":120},"What main themes emerged from the interviews?",{"text":121,"@type":113},"The study identified five themes, including a continuum of wariness to support, specialty differences in prescribing and care approaches, varied risk-benefit communication, implementation variation across practices and systems, and emotional/ethical complexity when evidence is limited.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},426724,1791063302,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81},962090760505,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Innovation in Aging, 2025, Vol. 9, No. S2 1193  \nAbstract citation ID: igaf122.3992  \nPERCEPTIONS OF VALUE AND ADOPTION OF ADRD  \nMODIFYING DRUGS AMONG PHYSICIANS AROUND  \nTHE U.S.  \nDinithi Perera1, Michelle Keller1, Zaldy Tan2, Chanelle Mizrahi1, Nabeel Qureshi3, Golnaz Yadollahikhales2, and Sarah Kremen2, 1. University of Southern California, Los Angeles, California, United States, 2. Cedars-Sinai Medical Center, Los Angeles, California, United States, 3. Cedars-Sinai Medical Centers, Los Angeles, California, United States  \nFollowing recent FDA approvals in the U.S. of two anti-amyloid medications for Alzheimer’s Disease, lecanemab and donanemab, we aimed to examine clinicians’ perceptions of the value of and real-world adoption experiences with prescribing these medications. While these monoclonal antibody treatments are the first medications to clear amyloid in the brain, they come with significant treatment burdens and risks. Our objective was to better understand the risk-benefit evaluations physicians make when selecting candidates for treatment; the practice-level, insurance, and health system obstacles they’ve had to navigate when implementing these complex medications into their practices; and how they communicate the risks and benefits to patients and their families. Using purposive and snowball sampling, we interviewed 10 physicians including geriatricians, neurologists and psychiatrists to understand the drivers of and barriers to adoption of these medications by physicians. We identified 5 themes from our qualitative interviews: 1) a broad continuum of wariness to avid proponent of the medications; 2) differences in a propensity to prescribe these medications and approaches to care between different clinical specialties, with strong support from neurologists and a more cautious approach from geriatricians;  \n3) varied communication styles in how physicians present the risks and benefits with patients and their families, 4) significant variation in practice and health-system implementation, from a planned approach to a less organized approach, and 5) clinicians facing shifting roles of balancing hope with limited data, managing ethical complexity, and bearing the emotional weight of guiding patients through novel therapies.","cbCaimiywjEQSeOI","https://ap.wps.com/l/cbCaimiywjEQSeOI","pdf",1047745,"English","# Abstract\n## Objectives and context\n## Methods\n## Qualitative themes","[{\"question\":\"What was the study aiming to understand about anti-amyloid medications?\",\"answer\":\"It examined clinicians’ perceptions of the value of lecanemab and donanemab and their real-world experiences adopting these therapies in practice.\"},{\"question\":\"How did the researchers gather evidence?\",\"answer\":\"They used purposive and snowball sampling to interview 10 physicians, including geriatricians, neurologists, and psychiatrists.\"},{\"question\":\"What main themes emerged from the interviews?\",\"answer\":\"The study identified five themes, including a continuum of wariness to support, specialty differences in prescribing and care approaches, varied risk-benefit communication, implementation variation across practices and systems, and emotional/ethical complexity when evidence is limited.\"}]","Perceptions of Value and Adoption of ADRD Modifying Drugs Among Physicians Around the U.S. | PDF",1790641599]